William Blair reiterates Amgen stock rating on positive Tepezza data By Investing.com

Amgen's Phase III subcutaneous TEPEZZA trial showed a 77% proptosis response rate vs 20% for placebo over 24 weeks, with results arriving earlier than its prior guidance for study completion in H2 2026. Analysts (William Blair, RBC) reiterated Outperform ratings and InvestingPro flags Amgen as potentially undervalued relative to fair value; company fundamentals cited include $36.75B revenue and a P/E of 24. The positive readthrough versus Viridian’s elegrobart and the potential for an on-body injector to expand access suggest meaningful upside to the TEPEZZA franchise and could move Amgen shares by a few percent.

Analysis

A major biologic shifting from infusion to an on‑body/subcutaneous delivery is a structural demand expansion story rather than a one‑quarter uplift: removing infusion capacity as the gating constraint can plausibly expand the treatable patient pool materially — our baseline is a 25–50% addressable increase over 12–36 months in markets where infusion access is the binding constraint — but realization depends on three operational levers (device usability, payer coding/reimbursement, and salesforce reorientation).

Second‑order winners include device suppliers (micro‑pump, sensor, adhesive manufacturers) and ambulatory care channels that can support at‑home initiation; losers are facility revenue streams tied to administration (infusion suites) and small regional infusion chains. Margin effects are ambiguous: substitution lowers professional/facility billings (pressure on top‑line per‑patient revenue) but reduces cost‑to‑serve and may increase share of high‑margin product revenue — net gross margin impact will hinge on device per‑unit cost and negotiated net price concessions.

Key near‑term catalysts to watch are (1) labeling language on who may administer the device, (2) CMS/insurer coding and reimbursement guidance (J/CPT code timing), and (3) early real‑world adherence/usability signals; any negative surprise on these fronts can compress the story quickly within 3–6 months. Consensus appears to price in relatively quick uptake; the contrarian risk is a drawn‑out conversion (12–24 months) with transient revenue cannibalization, which makes time‑barred, asymmetrical option structures more attractive than straight leverage on the equity.

Key Decisions for Investors

• Long AMGN (core holding) — accumulate into 2 tranches over the next 4–8 weeks on news digestion; target 12–18 month holding period to capture TAM expansion, trim into upside between +15%–25%.
• Buy AMGN LEAP calls (Jan 2028) or 12–18 month call spreads to capture asymmetric upside while limiting premium decay — size at 1–2% notional of portfolio; if device adoption delays >12 months, expect time premium erosion and consider stop at 50% of premium.
• Pair trade: long AMGN / short VRDN (Viridian) — initiate now, 6–18 month horizon. Rationale: Amgen’s incumbent scale and payer leverage should compress Viridian’s launch economics; target spread capture of 15–30% relative move, use 20% notional net exposure with a 25% stop on the short leg.
• Event hedge: buy a small position in an at‑the‑money put spread on AMGN expiring 6–9 months out to protect against regulatory, device, or reimbursement setbacks — cost should be <2% of position notional to maintain asymmetric upside.
• Monitor reimbursement and labeling calendar closely; if CMS issues favorable coding within 90 days, increase equity and call exposure; if labeling mandates clinic administration or early device failures are reported, rotate to hedges and consider reducing position by 25–40% within 1 week.